AbstractThis prospective phase II study evaluated a regimen with vincristine, oral idarubicin and dexamethasone (VID) in 74 patients with multiple myeloma. A partial response was achieved in 57% (16/28) of patients with previously untreated disease and in 35% (16/46) with refractory diseases. VID chemotherapy is an effective and tolerable oral alternative in an outpatient setting for these patients.
Figures & Tables
Vol. 89 No. 3 (2004): March, 2004 : Clinical Trial, Phase II
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com